321 related articles for article (PubMed ID: 26765686)
21. State of the art and future perspectives for the use of insulin-like growth factor receptor 1 (IGF-1R) targeted treatment strategies in solid tumors.
Scartozzi M; Bianconi M; Maccaroni E; Giampieri R; Del Prete M; Berardi R; Cascinu S
Discov Med; 2011 Feb; 11(57):144-53. PubMed ID: 21356169
[TBL] [Abstract][Full Text] [Related]
22. Genetic blockade of the insulin-like growth factor 1 receptor for human malignancy.
Adachi Y; Lee CT; Carbone DP
Novartis Found Symp; 2004; 262():177-89; discussion 190-2, 265-8. PubMed ID: 15562829
[TBL] [Abstract][Full Text] [Related]
23. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.
Kurmasheva RT; Dudkin L; Billups C; Debelenko LV; Morton CL; Houghton PJ
Cancer Res; 2009 Oct; 69(19):7662-71. PubMed ID: 19789339
[TBL] [Abstract][Full Text] [Related]
24. Targeting the insulin growth factor pathway in gastrointestinal cancers.
Golan T; Javle M
Oncology (Williston Park); 2011 May; 25(6):518-26, 529. PubMed ID: 21717907
[TBL] [Abstract][Full Text] [Related]
25. Targeting the DNA repair pathway in Ewing sarcoma.
Stewart E; Goshorn R; Bradley C; Griffiths LM; Benavente C; Twarog NR; Miller GM; Caufield W; Freeman BB; Bahrami A; Pappo A; Wu J; Loh A; Karlström Å; Calabrese C; Gordon B; Tsurkan L; Hatfield MJ; Potter PM; Snyder SE; Thiagarajan S; Shirinifard A; Sablauer A; Shelat AA; Dyer MA
Cell Rep; 2014 Nov; 9(3):829-41. PubMed ID: 25437539
[TBL] [Abstract][Full Text] [Related]
26. IGF-1R/MDM2 relationship confers enhanced sensitivity to RITA in Ewing sarcoma cells.
Di Conza G; Buttarelli M; Monti O; Pellegrino M; Mancini F; Pontecorvi A; Scotlandi K; Moretti F
Mol Cancer Ther; 2012 Jun; 11(6):1247-56. PubMed ID: 22461661
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models.
Beltran PJ; Chung YA; Moody G; Mitchell P; Cajulis E; Vonderfecht S; Kendall R; Radinsky R; Calzone FJ
J Pharmacol Exp Ther; 2011 Jun; 337(3):644-54. PubMed ID: 21385891
[TBL] [Abstract][Full Text] [Related]
28. Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: current hurdles and future perspectives.
Fleuren ED; Versleijen-Jonkers YM; Boerman OC; van der Graaf WT
Biochim Biophys Acta; 2014 Apr; 1845(2):266-76. PubMed ID: 24582852
[TBL] [Abstract][Full Text] [Related]
29. Does insulin-like growth factor 1 receptor (IGF-1R) targeting provide new treatment options for chordomas? A retrospective clinical and immunohistochemical study.
Scheipl S; Froehlich EV; Leithner A; Beham A; Quehenberger F; Mokry M; Stammberger H; Varga PP; Lazáry A; Windhager R; Gattenloehner S; Liegl B
Histopathology; 2012 May; 60(6):999-1003. PubMed ID: 22372631
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells.
Scotlandi K; Maini C; Manara MC; Benini S; Serra M; Cerisano V; Strammiello R; Baldini N; Lollini PL; Nanni P; Nicoletti G; Picci P
Cancer Gene Ther; 2002 Mar; 9(3):296-307. PubMed ID: 11896447
[TBL] [Abstract][Full Text] [Related]
31. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
Ozkan EE
Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
[TBL] [Abstract][Full Text] [Related]
32. Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells.
Bertrand FE; Steelman LS; Chappell WH; Abrams SL; Shelton JG; White ER; Ludwig DL; McCubrey JA
Leukemia; 2006 Jul; 20(7):1254-60. PubMed ID: 16642049
[TBL] [Abstract][Full Text] [Related]
33. Modeling Stroma-Induced Drug Resistance in a Tissue-Engineered Tumor Model of Ewing Sarcoma.
Santoro M; Menegaz BA; Lamhamedi-Cherradi SE; Molina ER; Wu D; Priebe W; Ludwig JA; Mikos AG
Tissue Eng Part A; 2017 Jan; 23(1-2):80-89. PubMed ID: 27923328
[TBL] [Abstract][Full Text] [Related]
34. [PARP inhibitors for cancer therapy].
Saito H; Miki Y
Gan To Kagaku Ryoho; 2011 Jan; 38(1):12-8. PubMed ID: 21368455
[TBL] [Abstract][Full Text] [Related]
35. Poly(ADP-ribose) polymerase 1 inhibition prevents interleukin-1β-induced inflammation in human osteoarthritic chondrocytes.
Sun Y; Zhou L; Lv D; Liu H; He T; Wang X
Acta Biochim Biophys Sin (Shanghai); 2015 Jun; 47(6):422-30. PubMed ID: 25926140
[TBL] [Abstract][Full Text] [Related]
36. Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group.
Vo KT; Edwards JV; Epling CL; Sinclair E; Hawkins DS; Grier HE; Janeway KA; Barnette P; McIlvaine E; Krailo MD; Barkauskas DA; Matthay KK; Womer RB; Gorlick RG; Lessnick SL; Mackall CL; DuBois SG
Clin Cancer Res; 2016 Jul; 22(14):3643-50. PubMed ID: 26861456
[TBL] [Abstract][Full Text] [Related]
37. Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma.
Friedrichs N; Küchler J; Endl E; Koch A; Czerwitzki J; Wurst P; Metzger D; Schulte JH; Holst MI; Heukamp LC; Larsson O; Tanaka S; Kawai A; Wardelmann E; Buettner R; Pietsch T; Hartmann W
J Pathol; 2008 Dec; 216(4):428-39. PubMed ID: 18855347
[TBL] [Abstract][Full Text] [Related]
38. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target.
Scotlandi K; Benini S; Sarti M; Serra M; Lollini PL; Maurici D; Picci P; Manara MC; Baldini N
Cancer Res; 1996 Oct; 56(20):4570-4. PubMed ID: 8840962
[TBL] [Abstract][Full Text] [Related]
39. Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade.
Iams WT; Lovly CM
Clin Cancer Res; 2015 Oct; 21(19):4270-7. PubMed ID: 26429980
[TBL] [Abstract][Full Text] [Related]
40. Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.
Guo Q; Yang Q; Li J; Liu G; Nikoulin I; Jia S
Curr Pharm Biotechnol; 2018; 19(14):1114-1121. PubMed ID: 30585545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
